Opioid-Induced Constipation Market - Global Outlook and Forecast 2021-2027

Name: Opioid-Induced Constipation Market - Global Outlook and Forecast 2021-2027
Brand: KnowledgeNJournals Research
SKU: Pharmaceuticals and Healthcare
Price: 3250 USD
Availability: InStock
Rating: 4.5 (37 reviews)

Report Code: KNJ777005 | No. of Pages: 105 | Category: Pharmaceuticals and Healthcare
Publisher: Market Monitor Global | Date of Publish: Jun-2021

This report contains market size and forecasts of Opioid-Induced Constipation in global, including the following market information:
Global Opioid-Induced Constipation Market Revenue, 2016-2021, 2022-2027, ($ millions)
Global Opioid-Induced Constipation Market Sales, 2016-2021, 2022-2027, (K Units)
Global top five Opioid-Induced Constipation companies in 2020 (%)
The global Opioid-Induced Constipation market was valued at 2652.9 million in 2020 and is projected to reach US$ 3151.9 million by 2027, at a CAGR of 4.4% during the forecast period.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Opioid-Induced Constipation manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global Opioid-Induced Constipation Market, By Type, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Opioid-Induced Constipation Market Segment Percentages, By Type, 2020 (%)
    Methylnaltrexone Bromide
    Lubiprostone
    Naloxegol
    Others

Global Opioid-Induced Constipation Market, By Application, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Opioid-Induced Constipation Market Segment Percentages, By Application, 2020 (%)
    Hospital
    Pharmacy

Global Opioid-Induced Constipation Market, By Region and Country, 2016-2021, 2022-2027 ($ Millions) & (K Units)
Global Opioid-Induced Constipation Market Segment Percentages, By Region and Country, 2020 (%)
    North America
        US
        Canada
        Mexico
    Europe
        Germany
        France
        U.K.
        Italy
        Russia
        Nordic Countries
        Benelux
        Rest of Europe
    Asia
        China
        Japan
        South Korea
        Southeast Asia
        India
        Rest of Asia
    South America
        Brazil
        Argentina
        Rest of South America
    Middle East & Africa
        Turkey
        Israel
        Saudi Arabia
        UAE
        Rest of Middle East & Africa

Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies Opioid-Induced Constipation revenues in global market, 2016-2021 (Estimated), ($ millions)
Key companies Opioid-Induced Constipation revenues share in global market, 2020 (%)
Key companies Opioid-Induced Constipation sales in global market, 2016-2021 (Estimated), (K Units)
Key companies Opioid-Induced Constipation sales share in global market, 2020 (%)
Further, the report presents profiles of competitors in the market, key players include:
    Takeda Pharmaceuticals
    Bayer
    Sanofi
    Mallinckrodt
    Salix (Bausch Health)
    AstraZeneca
    Progenics Pharmaceuticals
    Purdue Pharm
    Nektar Therapeutics
    Daiichi Sankyo
    Prestige
    GSK
    Shionogi

1 Introduction to Research & Analysis Reports
    1.1 Opioid-Induced Constipation Market Definition
    1.2 Market Segments
        1.2.1 Market by Type
        1.2.2 Market by Application
    1.3 Global Opioid-Induced Constipation Market Overview
    1.4 Features & Benefits of This Report
    1.5 Methodology & Sources of Information
        1.5.1 Research Methodology
        1.5.2 Research Process
        1.5.3 Base Year
        1.5.4 Report Assumptions & Caveats
2 Global Opioid-Induced Constipation Overall Market Size
    2.1 Global Opioid-Induced Constipation Market Size: 2021 VS 2027
    2.2 Global Opioid-Induced Constipation Revenue, Prospects & Forecasts: 2016-2027
    2.3 Global Opioid-Induced Constipation Sales (Consumption): 2016-2027
3 Company Landscape
    3.1 Top Opioid-Induced Constipation Players in Global Market
    3.2 Top Global Opioid-Induced Constipation Companies Ranked by Revenue
    3.3 Global Opioid-Induced Constipation Revenue by Companies
    3.4 Global Opioid-Induced Constipation Sales by Companies
    3.5 Global Opioid-Induced Constipation Price by Manufacturer (2016-2021)
    3.6 Top 3 and Top 5 Opioid-Induced Constipation Companies in Global Market, by Revenue in 2020
    3.7 Global Manufacturers Opioid-Induced Constipation Product Type
    3.8 Tier 1, Tier 2 and Tier 3 Opioid-Induced Constipation Players in Global Market
        3.8.1 List of Global Tier 1 Opioid-Induced Constipation Companies
        3.8.2 List of Global Tier 2 and Tier 3 Opioid-Induced Constipation Companies
4 Sights by Product
    4.1 Overview
        4.1.1 By Type - Global Opioid-Induced Constipation Market Size Markets, 2021 & 2027
        4.1.2 Methylnaltrexone Bromide
        4.1.3 Lubiprostone
        4.1.4 Naloxegol
        4.1.5 Others
    4.2 By Type - Global Opioid-Induced Constipation Revenue & Forecasts
        4.2.1 By Type - Global Opioid-Induced Constipation Revenue, 2016-2021
        4.2.2 By Type - Global Opioid-Induced Constipation Revenue, 2022-2027
        4.2.3 By Type - Global Opioid-Induced Constipation Revenue Market Share, 2016-2027
    4.3 By Type - Global Opioid-Induced Constipation Sales & Forecasts
        4.3.1 By Type - Global Opioid-Induced Constipation Sales, 2016-2021
        4.3.2 By Type - Global Opioid-Induced Constipation Sales, 2022-2027
        4.3.3 By Type - Global Opioid-Induced Constipation Sales Market Share, 2016-2027
    4.4 By Type - Global Opioid-Induced Constipation Price (Manufacturers Selling Prices), 2016-2027
5 Sights by Application
    5.1 Overview
        5.1.1 By Application - Global Opioid-Induced Constipation Market Size, 2021 & 2027
        5.1.2 Hospital
        5.1.3 Pharmacy
    5.2 By Application - Global Opioid-Induced Constipation Revenue & Forecasts
        5.2.1 By Application - Global Opioid-Induced Constipation Revenue, 2016-2021
        5.2.2 By Application - Global Opioid-Induced Constipation Revenue, 2022-2027
        5.2.3 By Application - Global Opioid-Induced Constipation Revenue Market Share, 2016-2027
    5.3 By Application - Global Opioid-Induced Constipation Sales & Forecasts
        5.3.1 By Application - Global Opioid-Induced Constipation Sales, 2016-2021
        5.3.2 By Application - Global Opioid-Induced Constipation Sales, 2022-2027
        5.3.3 By Application - Global Opioid-Induced Constipation Sales Market Share, 2016-2027
    5.4 By Application - Global Opioid-Induced Constipation Price (Manufacturers Selling Prices), 2016-2027
6 Sights by Region
    6.1 By Region - Global Opioid-Induced Constipation Market Size, 2021 & 2027
    6.2 By Region - Global Opioid-Induced Constipation Revenue & Forecasts
        6.2.1 By Region - Global Opioid-Induced Constipation Revenue, 2016-2021
        6.2.2 By Region - Global Opioid-Induced Constipation Revenue, 2022-2027
        6.2.3 By Region - Global Opioid-Induced Constipation Revenue Market Share, 2016-2027
    6.3 By Region - Global Opioid-Induced Constipation Sales & Forecasts
        6.3.1 By Region - Global Opioid-Induced Constipation Sales, 2016-2021
        6.3.2 By Region - Global Opioid-Induced Constipation Sales, 2022-2027
        6.3.3 By Region - Global Opioid-Induced Constipation Sales Market Share, 2016-2027
    6.4 North America
        6.4.1 By Country - North America Opioid-Induced Constipation Revenue, 2016-2027
        6.4.2 By Country - North America Opioid-Induced Constipation Sales, 2016-2027
        6.4.3 US Opioid-Induced Constipation Market Size, 2016-2027
        6.4.4 Canada Opioid-Induced Constipation Market Size, 2016-2027
        6.4.5 Mexico Opioid-Induced Constipation Market Size, 2016-2027
    6.5 Europe
        6.5.1 By Country - Europe Opioid-Induced Constipation Revenue, 2016-2027
        6.5.2 By Country - Europe Opioid-Induced Constipation Sales, 2016-2027
        6.5.3 Germany Opioid-Induced Constipation Market Size, 2016-2027
        6.5.4 France Opioid-Induced Constipation Market Size, 2016-2027
        6.5.5 U.K. Opioid-Induced Constipation Market Size, 2016-2027
        6.5.6 Italy Opioid-Induced Constipation Market Size, 2016-2027
        6.5.7 Russia Opioid-Induced Constipation Market Size, 2016-2027
        6.5.8 Nordic Countries Opioid-Induced Constipation Market Size, 2016-2027
        6.5.9 Benelux Opioid-Induced Constipation Market Size, 2016-2027
    6.6 Asia
        6.6.1 By Region - Asia Opioid-Induced Constipation Revenue, 2016-2027
        6.6.2 By Region - Asia Opioid-Induced Constipation Sales, 2016-2027
        6.6.3 China Opioid-Induced Constipation Market Size, 2016-2027
        6.6.4 Japan Opioid-Induced Constipation Market Size, 2016-2027
        6.6.5 South Korea Opioid-Induced Constipation Market Size, 2016-2027
        6.6.6 Southeast Asia Opioid-Induced Constipation Market Size, 2016-2027
        6.6.7 India Opioid-Induced Constipation Market Size, 2016-2027
    6.7 South America
        6.7.1 By Country - South America Opioid-Induced Constipation Revenue, 2016-2027
        6.7.2 By Country - South America Opioid-Induced Constipation Sales, 2016-2027
        6.7.3 Brazil Opioid-Induced Constipation Market Size, 2016-2027
        6.7.4 Argentina Opioid-Induced Constipation Market Size, 2016-2027
    6.8 Middle East & Africa
        6.8.1 By Country - Middle East & Africa Opioid-Induced Constipation Revenue, 2016-2027
        6.8.2 By Country - Middle East & Africa Opioid-Induced Constipation Sales, 2016-2027
        6.8.3 Turkey Opioid-Induced Constipation Market Size, 2016-2027
        6.8.4 Israel Opioid-Induced Constipation Market Size, 2016-2027
        6.8.5 Saudi Arabia Opioid-Induced Constipation Market Size, 2016-2027
        6.8.6 UAE Opioid-Induced Constipation Market Size, 2016-2027
7 Manufacturers & Brands Profiles
    7.1 Takeda Pharmaceuticals
        7.1.1 Takeda Pharmaceuticals Corporate Summary
        7.1.2 Takeda Pharmaceuticals Business Overview
        7.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Major Product Offerings
        7.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.1.5 Takeda Pharmaceuticals Key News
    7.2 Bayer
        7.2.1 Bayer Corporate Summary
        7.2.2 Bayer Business Overview
        7.2.3 Bayer Opioid-Induced Constipation Major Product Offerings
        7.2.4 Bayer Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.2.5 Bayer Key News
    7.3 Sanofi
        7.3.1 Sanofi Corporate Summary
        7.3.2 Sanofi Business Overview
        7.3.3 Sanofi Opioid-Induced Constipation Major Product Offerings
        7.3.4 Sanofi Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.3.5 Sanofi Key News
    7.4 Mallinckrodt
        7.4.1 Mallinckrodt Corporate Summary
        7.4.2 Mallinckrodt Business Overview
        7.4.3 Mallinckrodt Opioid-Induced Constipation Major Product Offerings
        7.4.4 Mallinckrodt Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.4.5 Mallinckrodt Key News
    7.5 Salix (Bausch Health)
        7.5.1 Salix (Bausch Health) Corporate Summary
        7.5.2 Salix (Bausch Health) Business Overview
        7.5.3 Salix (Bausch Health) Opioid-Induced Constipation Major Product Offerings
        7.5.4 Salix (Bausch Health) Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.5.5 Salix (Bausch Health) Key News
    7.6 AstraZeneca
        7.6.1 AstraZeneca Corporate Summary
        7.6.2 AstraZeneca Business Overview
        7.6.3 AstraZeneca Opioid-Induced Constipation Major Product Offerings
        7.6.4 AstraZeneca Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.6.5 AstraZeneca Key News
    7.7 Progenics Pharmaceuticals
        7.7.1 Progenics Pharmaceuticals Corporate Summary
        7.7.2 Progenics Pharmaceuticals Business Overview
        7.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Major Product Offerings
        7.4.4 Progenics Pharmaceuticals Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.7.5 Progenics Pharmaceuticals Key News
    7.8 Purdue Pharm
        7.8.1 Purdue Pharm Corporate Summary
        7.8.2 Purdue Pharm Business Overview
        7.8.3 Purdue Pharm Opioid-Induced Constipation Major Product Offerings
        7.8.4 Purdue Pharm Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.8.5 Purdue Pharm Key News
    7.9 Nektar Therapeutics
        7.9.1 Nektar Therapeutics Corporate Summary
        7.9.2 Nektar Therapeutics Business Overview
        7.9.3 Nektar Therapeutics Opioid-Induced Constipation Major Product Offerings
        7.9.4 Nektar Therapeutics Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.9.5 Nektar Therapeutics Key News
    7.10 Daiichi Sankyo
        7.10.1 Daiichi Sankyo Corporate Summary
        7.10.2 Daiichi Sankyo Business Overview
        7.10.3 Daiichi Sankyo Opioid-Induced Constipation Major Product Offerings
        7.10.4 Daiichi Sankyo Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.10.5 Daiichi Sankyo Key News
    7.11 Prestige
        7.11.1 Prestige Corporate Summary
        7.11.2 Prestige Opioid-Induced Constipation Business Overview
        7.11.3 Prestige Opioid-Induced Constipation Major Product Offerings
        7.11.4 Prestige Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.11.5 Prestige Key News
    7.12 GSK
        7.12.1 GSK Corporate Summary
        7.12.2 GSK Opioid-Induced Constipation Business Overview
        7.12.3 GSK Opioid-Induced Constipation Major Product Offerings
        7.12.4 GSK Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.12.5 GSK Key News
    7.13 Shionogi
        7.13.1 Shionogi Corporate Summary
        7.13.2 Shionogi Opioid-Induced Constipation Business Overview
        7.13.3 Shionogi Opioid-Induced Constipation Major Product Offerings
        7.13.4 Shionogi Opioid-Induced Constipation Sales and Revenue in Global (2016-2021)
        7.13.5 Shionogi Key News
8 Global Opioid-Induced Constipation Production Capacity, Analysis
    8.1 Global Opioid-Induced Constipation Production Capacity, 2016-2027
    8.2 Opioid-Induced Constipation Production Capacity of Key Manufacturers in Global Market
    8.3 Global Opioid-Induced Constipation Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
    9.1 Market Opportunities & Trends
    9.2 Market Drivers
    9.3 Market Restraints
10 Opioid-Induced Constipation Supply Chain Analysis
    10.1 Opioid-Induced Constipation Industry Value Chain
    10.2 Opioid-Induced Constipation Upstream Market
    10.3 Opioid-Induced Constipation Downstream and Clients
    10.4 Marketing Channels Analysis
        10.4.1 Marketing Channels
        10.4.2 Opioid-Induced Constipation Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
    12.1 Note
    12.2 Examples of Clients
    12.3 Disclaimer

Opioid-Induced Constipation Market - Global Outlook and Forecast 2021-2027

NEED Help?

USA : +1 (661) 636 6162

INDIA : +91 9325802062